Evidence map›Paper›PMID 34371806›Full record

Trial reportNutrients2021

The Effects of 12-Week Beta-Hydroxy-Beta-Methylbutyrate Supplementation in Patients with Liver Cirrhosis: Results from a Randomized Controlled Single-Blind Pilot Study.

Barbara Lattanzi, Angelo Bruni, Simone Di Cola, Alessio Molfino, Adriano De Santis, Maurizio Muscaritoli, Manuela Merli

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06149026 (Comparison of the Effect of Two Interventions on Liver Frailty Index in Pre-frail and Frail Cirrhotic Patients Enlisted for Liver Transplantation), which is not on this map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06149026 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Comparison of the Effect of Two Interventions on Liver Frailty Index in Pre-frail and Frail Cirrhotic Patients Enlisted for Liver Transplantation

TypeinterventionalSponsorPontificia Universidad Catolica de ChileRan2023 to 2023Enrolled80ConditionsCirrhosis, LiverArmsPhysical and nutritional therapy
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Observational
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Barbara LattanziGastroenterology, Department of Translational and Precision Medicine, "Sapienza" University, 00185 Rome, Italy.ORCID 0000-0003-2685-6504
Angelo BruniGastroenterology, Department of Translational and Precision Medicine, "Sapienza" University, 00185 Rome, Italy.
Simone Di ColaGastroenterology, Department of Translational and Precision Medicine, "Sapienza" University, 00185 Rome, Italy.
Alessio MolfinoInternal Medicine, Department of Translational and Precision Medicine, "Sapienza" University, 00185 Rome, Italy.
Adriano De SantisGastroenterology, Department of Translational and Precision Medicine, "Sapienza" University, 00185 Rome, Italy.ORCID 0000-0001-7338-9203
Maurizio MuscaritoliInternal Medicine, Department of Translational and Precision Medicine, "Sapienza" University, 00185 Rome, Italy.
Manuela MerliGastroenterology, Department of Translational and Precision Medicine, "Sapienza" University, 00185 Rome, Italy.ORCID 0000-0003-3173-9767
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimSarcopenia is considered an important risk factor for morbidity and mortality in liver cirrhosis. Beta-hydroxy-beta-methylbutyrate (HMB) has the potential to increase muscle mass and performance by stimulating protein synthesis and reducing muscle catabolism. The present study aimed at evaluating the effect of HMB supplementation on muscle mass and function in patients with liver cirrhosis. Changes in frailty during the study were also estimated, and the safety of HMB supplementation was verified.

methodsThis is a randomized, single-blind, placebo-controlled pilot trial. Twenty-four patients (14 HMB and 10 placebo) affected by liver cirrhosis were enrolled in the study. Each patient received dedicated counseling, which included nutrition and physical activity recommendations for chronic liver disease patients. Patients were randomized to receive 3 g/day of HMB or placebo (sorbitol powder) for 12 consecutive weeks. A diet interview, anthropometry, electrical bioimpedance analysis (BIA), quadriceps ultrasound, physical performance battery, Liver Frailty Index (LFI), and cognitive tests were completed at enrolment (T0), at 12 weeks (T1), and 24 weeks after enrolment (T2).

resultsAt baseline, the two groups were similar in demography, severity of liver disease, muscle mass, muscle function, and cognitive tests. LFI at baseline was higher in patients in the HMB group vs. those in the placebo group (4.1 ± 0.4 vs. 3.4 ± 0.6,

conclusionsOur study suggests the efficacy of 12-week beta-hydroxy-beta-methylbutyrate supplementation in promoting improvements in muscle performance in compensated cirrhotic patients. LFI was also ameliorated. Further studies with a greater number of patients are required to reinforce this hypothesis.

Indexed as

Dietary SupplementsAnthropometryElectric ImpedanceExerciseFemaleFrailtyHumansLiver CirrhosisMaleMiddle AgedMuscle, SkeletalMuscle StrengthPilot ProjectsSarcopeniaSingle-Blind MethodTreatment Outcomebeta-hydroxyisovaleric acidValeratesbeta-hydroxy-beta-methylbutyratefrailtyliver cirrhosissarcopenia

Identifiers

PMID34371806
PMCPMC8308449
OpenAlexW3173978967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.